Publishing research using ab39253? Please let us know so that we can cite the reference in this datasheet.

ab39253 has been referenced in 6 publications.

  • Zink LM  et al. H3.Y discriminates between HIRA and DAXX chaperone complexes and reveals unexpected insights into human DAXX-H3.3-H4 binding and deposition requirements. Nucleic Acids Res 45:5691-5706 (2017). PubMed: 28334823
  • Okada M  et al. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol 44:591-9 (2014). PubMed: 24316756
  • Viel T  et al. Optimizing Glioblastoma Temozolomide Chemotherapy Employing Lentiviral-based Anti-MGMT shRNA Technology. Mol Ther 21:570-9 (2013). PubMed: 23319055
  • Viel T  et al. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One 8:e67911 (2013). WB ; Human . PubMed: 23861829
  • Mendoza-Maldonado R  et al. The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation. Mol Cancer 10:83 (2011). IHC-P ; Human . PubMed: 21752281
  • Nakamichi I  et al. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol 86:557-64 (2007). IHC-P ; Human . PubMed: 17508213

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up